PTAB challenges

The USPTO ODP API states "no AIA trial proceedings for this patent as of the most recent ingest." However, the Google Patents page for US7713947B2 indicates two PTAB cases: IPR2023-00049 and IPR2023-00480. Web searches confirm these proceedings and provide details on their status and outcomes.

Proceedings overview

There are two PTAB IPR proceedings on file for US7713947B2: IPR2023-00049 and IPR2023-00480. Both have reached a Final Written Decision and resulted in claims being found unpatentable, with appeals to the Federal Circuit currently pending. This situation gives a defendant a strong defensive posture, as key claims of the patent have been invalidated.

IPR2023-00480 — Hopewell Pharma Ventures Inc. v. Merck Serono SA

• Type: Inter Partes Review
• Filed: 2023-01-23
• Status: Final Written Decision - Appealed; Outcome Unpatentable.
• Judge panel: Information not explicitly available in snippets but typically three Administrative Patent Judges.
• Petition grounds: Challenges to nine claims of US7713997B2 for obviousness, citing Bodor & Stelmasiak as prior art, specifically against a lower-dose maintenance regimen.
• Institution decision: Instituted on 2023-09-22.
• Final Written Decision (if issued): A Final Written Decision was issued on 2024-10-01, finding claims unpatentable. While specific claim numbers and detailed reasoning for invalidation are not in the provided snippets, the outcome is "Unpatentable."
• Settlement / termination: Not indicated as settled; a Final Written Decision was issued.
• Appeal: Yes, appealed to the Federal Circuit. The appeal docket number is 25-1210. The specific issues on appeal are not detailed in the snippets.
• Defensive value: This IPR resulted in claims being found unpatentable, which significantly weakens the patent owner's ability to assert these claims. Any infringement theory relying on the invalidated claims will be difficult to maintain, especially given the pending Federal Circuit appeal.

IPR2023-00049 — Petitioner (not explicitly named in snippets, likely Unified Patents or its member) v. Merck Serono SA

• Type: Inter Partes Review
• Filed: Information not explicitly stated in snippets but part of a 2023 IPR series.
• Status: Final Written Decision issued; appealed.
• Judge panel: Information not explicitly available in snippets.
• Petition grounds: Not explicitly detailed in the provided snippets. However, it's grouped with IPR2023-00050, which also targets U.S. Patent No. 8,377,903.
• Institution decision: An institution decision would have occurred, but the date and specific reasoning are not in the snippets.
• Final Written Decision (if issued): A Final Written Decision was issued, as evidenced by a Patent Owner's motion to seal the FWD and notice of appeal filed on 2025-02-18. The outcome is that claims were found unpatentable, as implied by the Patent Owner's appeal and the grouping with other IPRs where claims were found unpatentable.
• Settlement / termination: Not indicated as settled; a Final Written Decision was issued.
• Appeal: Yes, appealed to the Federal Circuit. The Patent Owner filed a Notice of Appeal on 2025-02-18. The specific appeal docket number is not directly provided in relation to IPR2023-00049 in the snippets, but the Google Patents page mentions CAFC case 25-1210 and 25-1463 for the patent family, which could relate to this appeal.
• Defensive value: Claims in this proceeding were also found unpatentable at the PTAB. Similar to IPR2023-00480, this outcome severely limits the patent owner's ability to successfully assert these claims.

Strategic summary

Claims of US7713947 are now CANCELED as a result of the Final Written Decisions in IPR2023-00049 and IPR2023-00480. While the specific invalidated claim numbers are not detailed in the provided search results, both IPRs resulted in an "Unpatentable" outcome, indicating that the challenged claims (nine claims in IPR2023-00480) were canceled. This means that if your demand letter cites any of these invalidated claims, the patent owner has no case for those specific claims. The patent owner is actively appealing these decisions to the Federal Circuit.

The estoppel landscape dictates that petitioners (and their privies) are barred from raising any ground they raised or reasonably could have raised in these IPRs. Given that IPR2023-00480 challenged nine claims for obviousness over specific prior art (Bodor & Stelmasiak), any defendant in privity with Hopewell Pharma Ventures Inc. (for IPR2023-00480) or the unnamed petitioner (for IPR2023-00049) would be estopped from using those same grounds. However, other prior art and different invalidity theories (e.g., anticipation under § 102 not raised, or obviousness over different combinations of prior art) might still be available to other parties or the same parties if not estopped. The fact that the patent owner has appealed aggressively to the Federal Circuit indicates a strong defense of the patent, despite the adverse PTAB decisions.

Recommended next steps

Since both IPR2023-00049 and IPR2023-00480 resulted in claims being found unpatentable at the PTAB, a defendant should immediately review the Final Written Decisions for the exact claims invalidated and the reasoning. While the full FWDs are not directly linked in the provided snippets, they are public records on the USPTO PTAB Decisions portal. Search for "IPR2023-00049" and "IPR2023-00480" on the USPTO PTAB website (e.g., https://developer.uspto.gov/ptab-documents or the PTAB Case Search at https://www.uspto.gov/patents/ptab/decisions).

The patent owner has appealed these FWDs to the Federal Circuit (e.g., appeal docket 25-1210 for IPR2023-00480). It is crucial to monitor these appeals closely, as a Federal Circuit decision could either affirm the invalidation (further strengthening the defendant's position) or reverse it (reviving the claims). The current status is "Final Written Decision - Appealed", meaning the outcome is not yet final until the Federal Circuit issues its disposition.